Dr. Kate Broderick leverages more than 20 years of life science experience with over 15 years in research and development as the head of Maravai's newly established Science and Innovation Office. A recognized expert in vaccine and nucleic acid technology, Dr. Broderick has led global teams and collaborated with industry, academic, and government partners to develop vaccines for a wide range of infectious diseases, including Ebola, MERS, Zika, HIV, Lassa fever, and COVID-19. Before joining Maravai in 2022, Dr. Broderick held roles of increasing responsibility at Inovio Pharmaceuticals, most recently as Senior Vice President of R&D Dr. Broderick received her PhD from the University of Glasgow in Scotland and completed post-doctoral research at the University of California, San Diego.